Banco Bilbao Vizcaya Argentaria S.A. Sells 2,240 Shares of Humana Inc. (NYSE:HUM)

Banco Bilbao Vizcaya Argentaria S.A. trimmed its holdings in Humana Inc. (NYSE:HUM - Free Report) by 21.4% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 8,240 shares of the insurance provider's stock after selling 2,240 shares during the quarter. Banco Bilbao Vizcaya Argentaria S.A.'s holdings in Humana were worth $2,092,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. FPC Investment Advisory Inc. bought a new stake in Humana in the 4th quarter worth about $27,000. Centricity Wealth Management LLC purchased a new position in Humana in the fourth quarter worth about $30,000. LFA Lugano Financial Advisors SA boosted its position in Humana by 56.3% in the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider's stock worth $32,000 after purchasing an additional 45 shares during the last quarter. OFI Invest Asset Management purchased a new position in Humana in the fourth quarter worth about $33,000. Finally, Transce3nd LLC purchased a new position in Humana in the fourth quarter worth about $38,000. 92.38% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

HUM has been the topic of several research reports. Royal Bank of Canada reissued an "outperform" rating and issued a $283.00 target price on shares of Humana in a research report on Wednesday, February 12th. Guggenheim assumed coverage on shares of Humana in a research note on Wednesday, April 9th. They set a "buy" rating and a $326.00 target price on the stock. Truist Financial upped their price target on shares of Humana from $290.00 to $325.00 and gave the stock a "hold" rating in a research report on Friday, April 11th. Robert W. Baird increased their price objective on shares of Humana from $270.00 to $300.00 and gave the stock a "neutral" rating in a research note on Tuesday, April 15th. Finally, Morgan Stanley reduced their price objective on shares of Humana from $301.00 to $285.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 12th. Seventeen investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Hold" and a consensus target price of $284.90.

Humana Price Performance

HUM stock traded down $4.29 during trading on Tuesday, hitting $258.91. 2,471,973 shares of the company's stock traded hands, compared to its average volume of 1,750,020. Humana Inc. has a 52 week low of $213.31 and a 52 week high of $406.46. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76. The business has a fifty day simple moving average of $266.05 and a 200 day simple moving average of $270.76. The stock has a market capitalization of $31.25 billion, a price-to-earnings ratio of 26.02, a P/E/G ratio of 2.05 and a beta of 0.62.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings data on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, beating the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. As a group, research analysts expect that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be given a dividend of $0.885 per share. The ex-dividend date is Friday, June 27th. This represents a $3.54 annualized dividend and a yield of 1.37%. Humana's dividend payout ratio (DPR) is currently 35.58%.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.